Prognostic value of Albumin-to-Alkaline Phosphatase Ratio (AAPR) in patients with hepatocellular carcinoma treated at Phrapokklao Hospital, Chanthaburi

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20260223002

Enrollment

350

Registered

2026-02-23

Start date

2026-08-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prognostic value of Albumin to Alkaline Phosphatase Ratio in patients with hepatocellular carcinoma Hepatocellular carcinoma, Albumin-to-Alkaline Phosphatase Ratio, AAPR, ALBI score, MELD score, Prognostic marker, Thailand

Interventions

HCC according to the criteria of AASLD which received treatment with surgical resection or TACE or systemic therapy

Screening

HCC patients

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1.Age older than 18 years 2.Diagnosed with HCC according to the criteria of AASLD 3.Availability of complete baseline laboratory data prior to initiation of treatment 4.Received treatment with Surgical resection or TACE or systemic therapy

Exclusion criteria

Exclusion criteria: 1.Prior treatment for HCC 2.Presence of concurrent malignancies 3.Incomplete data or loss to follow up within the first three months

Design outcomes

Primary

Measure	Time frame
Overall survival 2 years Albumin to Alkaline Phosphatase Ratio	—

Secondary

Measure	Time frame
Recurrence free survical 2 years Time to event analysis	—

Countries

Thailand

Contacts

Public ContactAchareeya Jangwanitlert

Prapokklao hospital

achareeyajangwanitlert@gmail.com0892627788

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026